Dianthus Therapeutics, Inc. $DNTH Shares Purchased by RA Capital Management L.P.

Key Points

• RA Capital Management L.P. increased its holdings in Dianthus Therapeutics by 53.6%, acquiring an additional 1,000,333 shares, making it the fund's 23rd largest position.
• Dianthus Therapeutics reported a quarterly loss of ($0.88) EPS, missing the consensus estimate, while revenue fell short of expectations at $0.19 million.
• Wall Street analysts are generally optimistic, with several firms issuing "outperform" ratings and a target price range averaging around $54.00 for the stock.

RA Capital Management L.P. lifted its position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) by 53.6% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,866,733 shares of the company's stock after buying an additional 1,000,333 shares during the period. Dianthus Therapeutics makes up about 0.9% of RA Capital Management L.P.'s portfolio, making the stock its 23rd largest position. RA Capital Management L.P. owned approximately 8.92% of Dianthus Therapeutics worth $52,003,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of DNTH. US Bancorp DE grew its position in shares of Dianthus Therapeutics by 2,013.3% in the 1st quarter. US Bancorp DE now owns 1,585 shares of the company's stock worth $29,000 after buying an additional 1,510 shares during the last quarter. BNP Paribas Financial Markets purchased a new position in shares of Dianthus Therapeutics in the 4th quarter worth approximately $59,000. GAMMA Investing LLC grew its position in shares of Dianthus Therapeutics by 3,030.6% in the 1st quarter. GAMMA Investing LLC now owns 3,882 shares of the company's stock worth $70,000 after buying an additional 3,758 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Dianthus Therapeutics by 21.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 9,468 shares of the company's stock worth $207,000 after buying an additional 1,647 shares during the last quarter. Finally, Invesco Ltd. grew its position in shares of Dianthus Therapeutics by 7.4% in the 4th quarter. Invesco Ltd. now owns 11,521 shares of the company's stock worth $251,000 after buying an additional 790 shares during the last quarter. Hedge funds and other institutional investors own 47.53% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. William Blair initiated coverage on shares of Dianthus Therapeutics in a research report on Wednesday, July 2nd. They issued an "outperform" rating on the stock. Robert W. Baird dropped their price objective on shares of Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating on the stock in a report on Tuesday, May 13th. HC Wainwright reissued a "buy" rating and set a $40.00 price target on shares of Dianthus Therapeutics in a report on Tuesday, May 13th. Finally, Wedbush increased their price target on shares of Dianthus Therapeutics from $34.00 to $42.00 and gave the stock an "outperform" rating in a report on Thursday, August 21st. Seven research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $54.00.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ DNTH traded up $0.40 during mid-day trading on Thursday, reaching $24.66. The company's stock had a trading volume of 348,965 shares, compared to its average volume of 335,391. The stock has a 50-day moving average of $21.10 and a two-hundred day moving average of $20.06. The stock has a market capitalization of $793.81 million, a P/E ratio of -7.59 and a beta of 1.46. Dianthus Therapeutics, Inc. has a 1-year low of $13.36 and a 1-year high of $32.27.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.02). The business had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.87 million. Dianthus Therapeutics had a negative net margin of 2,364.56% and a negative return on equity of 34.72%. Analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.